

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Apremilast immediate release 30 mg (Otezla IR 30 mg)

Notes:

- Quantity Limits: Yes
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- ^ Adequate trial is defined as the following:
 - Phototherapy – 8 weeks
 - Methotrexate for psoriatic arthritis – 3 months
 - Topical steroids and colchicine for Behçet's disease – 3 months
 - Psoriasis systemic medications – 6 weeks

Initiation (new start) criteria: Formulary **apremilast immediate release 30 mg (Otezla IR 30 mg)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
 - Patient is 6 years of age or older
 - Patient weighs 50 kg or more
 - Patient has failed an adequate trial^ of phototherapy (unless documented by prescriber phototherapy not appropriate)
 - Patient has tried and failed an adequate trial^ of, or patient has an allergy or intolerance* to at least 1 of the following systemic medications (or contraindication to all):
 - Methotrexate
 - Cyclosporine
 - Acitretin
 - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
2. Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient is 6 years of age or older
 - Patient weighs 50 kg or more
 - Patient has failed an adequate trial^, has an intolerance* to, or has a contraindication to methotrexate (methotrexate not required if patient has dactylitis [inflammation of finger or toe] and/or enthesitis [inflammation of the entheses])
 - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Apremilast immediate release 30 mg (Otezla IR 30 mg)

3. Prescriber is a rheumatologist and patient has a diagnosis of oral ulcers associated with Behcet's disease
 - Patient is 18 years of age or older
 - Patient weighs 50 kg or more
 - Patient has failed an adequate trial[^], has an intolerance* to, or has a contraindication to the following:
 - Topical steroids
 - Colchicine

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Formulary **apremilast immediate release 30 mg (Otezla IR 30 mg)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
 - Patient is 6 years of age or older
 - Patient weighs 50 kg or more
 - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
2. Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient is 6 years of age or older
 - Patient weighs 50 kg or more
 - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
3. Prescriber is a rheumatologist and patient has a diagnosis of oral ulcers associated with Behçet's disease
 - Patient is 18 years of age or older
 - Patient weighs 50 kg or more

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Apremilast immediate release 30 mg (Otezla IR 30 mg)

Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Formulary **apremilast immediate release 30 mg (Otezla IR 30 mg)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

1. Prescriber is a dermatologist and patient has a diagnosis of psoriasis
 - Patient has responded to apremilast as determined by prescriber
 - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
2. Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient has responded to apremilast as determined by prescriber
 - Patient does not currently have an active prescription for a biologic DMARD or a Janus kinase inhibitor (oral or topical)
3. Prescriber rheumatologist and patient has a diagnosis of oral ulcers associated with Behçet's disease
 - Patient has responded to apremilast as determined by prescriber